This study tests a medicine called GSK4532990, which might help people with a liver problem called NASH (Non-Alcoholic Steatohepatitis). NASH is a liver disease caused by fat buildup, leading to inflammation and liver damage. The study will last up to 76 weeks, including a 52-week treatment period. Participants will receive either GSK4532990 or a placebo, which is a pill with no medicine in it, to see if the medication improves liver health. A liver biopsy, a small sample of the liver, will be taken to check for improvements.
Key Points:- The study lasts up to 76 weeks, with 52 weeks of treatment.
- Participants must be willing to undergo a liver biopsy at Week 52.
- Current alcohol consumption must be below a certain level to join.
Participants must have a BMI (Body Mass Index) of 25 or more, except for Asians, who can have a BMI of 23 or more. Conditions like type 2 diabetes, obesity, and high blood pressure are considered. Anyone with recent major weight-loss surgery or cancer history might not be eligible.